[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"contrast-enhanced-ultrasound\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:contrast-enhanced-ultrasound":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,43,66,102,134,159,182,208,230],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100641430","international-delphi-study-to-develop-standardized-quality-criteria-and-a-rating-tool-for-liver-ceus-image-quality-assessment-100641430",false,"NCT07656181","International Delphi Study to Develop Standardized Quality Criteria and a Rating Tool for Liver CEUS Image Quality Assessment","Delphi Study on Quality Indicators for CEUS Imaging of the Liver Using SonoVue® Contrast Agent","ICON LiverCEUS","Inclusion Criteria:\n\n* At least 6 years of active experience in ultrasound diagnostics in internal medicine, radiology, or a related clinical field\n* Independent performance of at least 5,000 ultrasound examinations Participation in structured CEUS training\n* Performance of at least 800 ultrasound examinations per year in routine clinical practice\n* Either: at least 100 independently performed CEUS examinations per year or more than 700 CEUS examinations in total\n* Regular participation in ultrasound-related meetings, case reviews, or quality assurance activities within their institution\n* Scientific involvement in CEUS, demonstrated by at least one peer-reviewed publication and\u002For active engagement in CEUS education or training\n* Signing the consent form of the participants\n\nExclusion Criteria:\n\n* Failure to meet the inclusion criteria",true,"ALL",{"count":20,"type":21},35,"ESTIMATED","OBSERVATIONAL","This study aims to establish international consensus-based quality criteria for contrast-enhanced ultrasound (CEUS) examinations of the liver and to develop a standardized tool for assessing CEUS image quality. CEUS is an established imaging technique used in clinical practice for the characterization and assessment of focal liver lesions and other liver abnormalities. Despite its increasing use, there are currently no universally accepted or validated standards for evaluating the quality and reproducibility of CEUS examinations.\n\nThe primary objective of this project is therefore to identify robust and clinically relevant quality indicators for liver CEUS examinations through an international Delphi consensus process. The study focuses specifically on CEUS examinations performed in adult patients using the ultrasound contrast agent SonoVue®.\n\nThe project is divided into two work packages (WP). In Work Package 1 (WP1), the study team will first conduct a structured review of the available literature and discuss potential CEUS quality criteria within the research group. Based on this process, an initial catalogue of quality indicators relating to technical, procedural, and imaging characteristics relevant to liver CEUS examinations will be developed.\n\nThese proposed criteria will subsequently be evaluated through a multi-round Delphi process involving an international and interdisciplinary panel of experienced CEUS users and experts. A minimum of 20 panellists will participate across all Delphi rounds. Participants will rate their level of agreement with each proposed quality criterion using a 7-point Likert scale and may suggest additional criteria where appropriate. Newly proposed criteria supported by more than 10% of participants will be included in subsequent Delphi rounds.\n\nDuring each round, panellists will receive anonymised feedback summarising the responses of the group and will be invited to re-evaluate the relevance of the proposed criteria. This iterative process will continue for at least three rounds or until predefined consensus criteria are achieved. Consensus will be defined as at least 70% agreement with a rating of 6 or higher on the Likert scale.\n\nIn Work Package 2 (WP2), the consensus-based quality criteria identified in WP1 will be operationalised into a comprehensive and standardized rating scale for CEUS image quality assessment. Individual criteria will be grouped into broader domains and transformed into practical assessment items and prompts. The resulting rating tool will then be circulated among all Delphi panel members for final review and feedback to ensure clarity, applicability, and international usability.\n\nThe overall goal of this study is to improve standardization, quality assurance, and reproducibility in liver CEUS examinations. The developed consensus criteria and rating scale may support clinical practice, future research studies, multicentre collaborations, and educational initiatives by enabling more consistent evaluation of CEUS image quality across institutions and countries.",[25,26,27],"Contrast Enhanced Ultrasound","Ultrasonic Diagnosis","Liver",[29],"Quality Indicators of Liver CEUS","RECRUITING","2026-06-22",{"date":33,"type":34},"2026-06-25","ACTUAL",{"date":36,"type":21},"2026-06-01",{"date":38,"type":21},"2026-09-30",{"name":40,"class":41},"University of Bern","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":57,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":4},"100638933","a-comparative-study-on-the-diagnostic-efficacy-of-ultrasound-contrast-li-rads-grading-and-the-german-esculap-standards-for-the-diagnosis-of-recurrent-hepatic-mass-lesions-after-hepatocellular-carcinoma-surgery-100638933","NCT07600346","A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery","Inclusion Criteria:\n\n* (1) At least 18 years old; (2) Has a previous history of liver cell cancer surgery or ablation, and has a newly developed liver lesion this time; (3) The new lesion completed a complete contrast-enhanced ultrasound examination within two weeks before the final diagnosis, and the dynamic imaging data is completely preserved; (4) The new lesion has a clear pathological or clinical diagnosis.\n\nExclusion Criteria:\n\n* (1) The quality of contrast-enhanced ultrasound images is poor, making it impossible to assess the critical phases; (2) New lesions that have been treated locally or systemically.","18 Years",{"count":51,"type":21},105,"Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide, with a significantly increased incidence among patients with liver diseases. Even if HCC can be treated by surgical resection and ablation, the 5-year recurrence rate is as high as 50-70%. The Liver Imaging Reporting and Data System (LI-RADS), released by the American College of Radiology (ACR), is a classification management system specifically designed to evaluate liver lesions in high-risk HCC patients. Since its release in 2011, the CT\u002FMRI LI-RADS has been updated to the 2018 version. Subsequently, the CEUS LI-RADS was introduced in 2016 and updated in 2017. The CEUS LI-RADS standard has relatively high specificity but lacks sensitivity. The ESCULAP (Erlanger Synopsis of Contrast-enhanced Ultrasound for Liver lesion Assessment in Patients at Risk) standard proposed by Schellhaas et al. in Germany has high sensitivity in diagnosing HCC in patients with liver diseases . However, there is currently a lack of research on the diagnostic efficacy of these two standards for the re-discovery of liver space-occupying lesions in patients with a history of HCC. This study aims to compare the diagnostic efficacy of the two standards for recurrent HCC in patients with a history of HCC.",[54,55],"Hepatocellular Carcinoma (HCC) Prognosis","Contrast-enhanced Ultrasound","NOT_YET_RECRUITING","2026-05-14",{"date":59,"type":34},"2026-05-20",{"date":61,"type":21},"2026-05-30",{"date":63,"type":21},"2027-05-30",{"name":65,"class":41},"The First Hospital of Jilin University",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":72,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":86,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":42},"100630837","multiparametric-ultrasound-for-the-noninvasive-diagnosis-of-porto-sinusoidal-vascular-liver-disorder-100630837","NCT07492862","Multiparametric Ultrasound for the Noninvasive Diagnosis of Porto-sinusoidal Vascular Liver Disorder","Explorative Study for the Application of Dynamic Contrast-enhanced Ultrasound for the Noninvasive Diagnosis of Porto-sinusoidal Vascular Liver Disorder","CEUS-PSVD","Inclusion criteria - PSVD group\n\n* Histologically confirmed diagnosis of porto-sinusoidal vascular disease (PSVD);\n* Presence of clinically significant portal hypertension, evidenced by at least one specific sign of portal hypertension (e.g., imaging evidence of collateral circulation or porto-systemic shunts, endoscopic evidence of esophageal or gastric varices, or history of gastrointestinal variceal bleeding);\n* Age ≥ 18 years;\n* Ability to understand the study information and provide written informed consent;\n\nInclusion criteria - Cirrhosis group\n\n* Diagnosis of liver cirrhosis confirmed by liver histology or, alternatively, by compatible findings on imaging, laboratory tests, and physical examination together with a positive history for at least one known cause of chronic liver disease;\n* Presence of clinically significant portal hypertension, evidenced by at least one specific sign of portal hypertension (e.g., imaging evidence of collateral circulation or porto-systemic shunts, endoscopic evidence of esophageal or gastric varices, or history of gastrointestinal variceal bleeding);\n* Age ≥ 18 years;\n* Ability to understand the study information and provide written informed consent.\n\nExclusion criteria - PSVD group (cases)\n\n* Presence of other causes of portal hypertension, including but not limited to: history of bone marrow transplantation, Budd-Chiari syndrome or hepatic venous outflow obstruction, hepatic schistosomiasis, Abernethy malformation, hereditary hemorrhagic telangiectasia, sarcoidosis, congenital hepatic fibrosis, or chronic cholestatic liver diseases;\n* Presence of portal, spleno-mesenteric, or hepatic vein thrombosis;\n* Prior hepatic or splenic surgery;\n* Presence of primary or secondary malignant liver tumors;\n* Presence of a transjugular intrahepatic portosystemic shunt (TIPS) device;\n* Congenital anomalies of the liver or biliary tract;\n* History of heart failure;\n* Contraindications to administration of SonoVue (sulfur hexafluoride microbubbles), including: prior allergic reaction to the active substance or any excipients, known right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure \\> 90 mmHg), uncontrolled systemic hypertension, or adult respiratory distress syndrome;\n* Inadequate sonographic visualization of the right hepatic lobe;\n* Pregnancy.\n\nExclusion criteria - Cirrhosis group\n\n* Decompensated cirrhosis or Child-Pugh class C;\n* Cryptogenic cirrhosis;\n* Presence of other causes of portal hypertension (same list as for PSVD exclusions: history of bone marrow transplantation, Budd-Chiari syndrome or hepatic venous outflow obstruction, hepatic schistosomiasis, Abernethy malformation, hereditary hemorrhagic telangiectasia, sarcoidosis, congenital hepatic fibrosis, chronic cholestatic diseases);\n* Presence of portal, spleno-mesenteric, or hepatic vein thrombosis;\n* Prior hepatic or splenic surgery;\n* Presence of primary or secondary malignant liver tumors;\n* Presence of a transjugular intrahepatic portosystemic shunt (TIPS) device;\n* Congenital anomalies of the liver or biliary tract;\n* History of heart failure;\n* Contraindications to administration of SonoVue (sulfur hexafluoride microbubbles), including: prior allergic reaction to the active substance or any excipients, known right-to-left shunts, severe pulmonary hypertension (pulmonary artery pressure \\> 90 mmHg), uncontrolled systemic hypertension, or adult respiratory distress syndrome;\n* Inadequate sonographic visualization of the right hepatic lobe;\n* Pregnancy.",{"count":75,"type":21},100,"INTERVENTIONAL",[78],"NA","Porto-sinusoidal vascular disease (PSVD) is a rare clinical entity characterized by significant portal hypertension in the absence of cirrhosis on liver histology, which may or may not show specific alterations of the portal vein, sinusoids, or hepatic lobular architecture. Currently, diagnosis of this condition necessarily requires a liver biopsy and, despite some differences detected on imaging studies-and particularly on liver and spleen elastography-PSVD remains indistinguishable from cirrhosis using non-invasive tests.\n\nContrast-enhanced ultrasound (CEUS) is an easy-to-perform, repeatable, and cost-effective examination that enables real-time assessment of parenchymal or focal liver lesion perfusion. Moreover, the application of dynamic contrast-enhanced ultrasound (DCE-US-i.e., contrast-enhanced ultrasound followed by quantitative perfusion analysis using dedicated software, such as the VueBox Software that will be used in this study) allows integration of CEUS qualitative assessment with quantitative evaluation of tissue perfusion through analysis of time-intensity curves generated during contrast transit. From this analysis, several perfusion-related parameters can be derived (for example, peak enhancement, time to peak, or area under the curve), which have already proven useful in improving differential diagnosis of focal liver lesions and in predicting treatment response and systemic therapy outcomes.\n\nTo date, the use of DCE-US for the diagnosis of PSVD has not yet been described; however, based on the underlying histological alterations associated with this disease, it is reasonable to hypothesize that parameters obtained with this technique in the liver parenchyma of patients with PSVD may differ from those measured in patients with liver cirrhosis. The aim of the present project is to apply DCE-US in patients with PSVD and in patients with cirrhosis to evaluate potential significant differences in perfusion parameters, and to assess the feasibility of a non-invasive differential diagnosis between the two conditions using this technique in combination with elastography and bidimensional ultrasound data to develop a multiparametric diagnostic score.",[81,82,83,84,85,55],"Porto-sinusoidal Vascular Liver Disorder","Liver Cirrhosis","Portal Hypertension, Noncirrhotic","Portal Hypertension Related to Cirrhosis","Ultrasound Elastography",[87,88,89,90,91,92],"porto-sinusoidal vascular liver disorder","liver cirrhosis","liver ultrasound","ultrasound elastography","dynamic contrast-enhanced ultrasound","chronic liver disease","2026-03-20",{"date":95,"type":34},"2026-03-25",{"date":97,"type":21},"2026-03",{"date":99,"type":21},"2028-12",{"name":101,"class":41},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":107,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":109,"minAge":49,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":76,"phases":112,"briefSummary":113,"conditions":114,"keywords":121,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":42},"100625403","placeus-feasibility-study-of-contrast-enhanced-ultrasound-to-visualize-maternal-uterine-spiral-arteries-postpartum-100625403","NCT07422181","PlaCEUS: Feasibility Study of Contrast-enhanced Ultrasound to Visualize Maternal Uterine Spiral Arteries Postpartum.","PlaCEUS","Inclusion Criteria:\n\n* Pregnant patient at a minimum age of 18 years\n* Singleton pregnancy at term (≥37 weeks gestation)\n* Planning to deliver at the Máxima Medical Centre\n* Able to provide informed consent\n* Intravenous access present at the time of delivery\n\nExclusion Criteria:\n\n* Multiple gestation pregnancy\n* Contra-indications to CEUS, e.g. known allergy for constituents of SonoVue™\n* Planning on breastfeeding\n* Medical emergency during or after delivery, which makes CEUS impossible or undesirable\n* No intravenous access present at the time of delivery\n* Body Mass Index \\>40 kg\u002Fm2.\n* Pre-eclampsia requiring medication\n* Foetal growth restriction \\\u003C p3","FEMALE",{"count":111,"type":21},5,[78],"During pregnancy, unique blood vessels form within the uterine wall, known as spiral arteries. These vessels originate from the uterine artery, which is the main artery supplying blood to the uterus. Throughout pregnancy, spiral arteries undergo significant changes to increase blood and oxygen flow to the placenta, ensuring the developing baby receives adequate nutrients. When these arteries fail to remodel properly, complications such as pre-eclampsia or fetal growth restriction can occur.\n\nUntil now, direct observation and evaluation of spiral arteries during pregnancy has not been feasible. Contrast-enhanced ultrasound may provide a breakthrough in this area. In this study, the investigators aim to use this imaging technique to visualize spiral arteries after the placenta has been delivered. If successful, this could allow to assess their structural quality. Additionally, the investigators will employ ultrasound to monitor physiological changes in the uterine artery during late pregnancy (after 37 weeks), during labour, and postpartum.\n\nBy conducting these measurements, the investigators hope to develop methods for detecting spiral artery abnormalities earlier in pregnancy. Early identification could enable timely interventions and help prevent severe complications.",[115,116,25,117,118,119,120],"Spiral Arteries","Uterine Artery Hemodynamics","Doppler Parameters","Resistance Index","Pulsatility Index","Systolic\u002FDiastolic Ratio",[122,123,124],"Spiral arteries","Uterine artery hemodynamics","contrast enchanced ultrasound","2026-02-12",{"date":127,"type":34},"2026-02-19",{"date":129,"type":34},"2025-12-17",{"date":131,"type":21},"2026-07-01",{"name":133,"class":41},"Maxima Medical Center",{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":143,"conditions":144,"keywords":146,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100620434","preoperative-prediction-of-lymph-node-metastasis-in-t1n0m0-papillary-thyroid-carcinoma-by-using-contrast-enhanced-ultrasound-100620434","NCT07357571","Preoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound","Multicenter Retrospective Study of Dual-mode Contrast-enhanced Ultrasound Predictive Model for Lymph Node Metastasis Burden in T1N0M0 Papillary Thyroid Carcinoma","Inclusion Criteria\n\n1. Patients with preoperative assessment of T1N0M0 papillary thyroid carcinoma who underwent initial surgical treatment at the medical centers participating in this study between June 2018 and June 2025.\n2. Definitive diagnosis of papillary thyroid carcinoma confirmed by postoperative histopathological examination.\n3. Preoperative conventional ultrasound and contrast-enhanced ultrasound (CEUS) examination of the thyroid and\u002For suspicious central lymph nodes were performed, with complete imaging data of acceptable quality for analysis.\n4. Surgical procedures included thyroidectomy (lobectomy or total thyroidectomy) combined with central lymph node dissection (prophylactic or therapeutic) to provide a definitive pathological gold standard for lymph nodes.\n5. Complete clinical pathological data and imaging data were retrievable from the Hospital Information System (HIS).\n\nExclusion Criteria\n\n1. Preoperative receipt of any anti-tumor treatment targeting the thyroid (e.g., radiotherapy, chemotherapy, targeted therapy, or ablation therapy).\n2. Complication with other types of thyroid malignant tumors (e.g., medullary carcinoma, undifferentiated carcinoma, etc.).\n3. History of neck surgery or radiotherapy that may affect the structure of cervical lymph nodes.\n4. Complication with other systemic diseases that may affect CEUS perfusion characteristics or imaging evaluation (e.g., severe heart failure, liver cirrhosis, etc.).\n5. Allergy to components of the ultrasound contrast agent.\n6. Missing key clinical or imaging data, making complete analysis impossible.",{"count":142,"type":21},600,"Similarly, the burden of central lymph node metastasis affects the individualized management of patients with T1N0M0 papillary thyroid carcinoma (PTC): lymph node metastasis is a contraindication to thermal ablation; low-burden lymph node metastasis is suitable for lobectomy; and high-burden lymph node metastasis recommends total thyroidectomy. However, conventional preoperative imaging examinations have low efficacy in diagnosing central lymph node metastasis. This multicenter retrospective cross-sectional study enrolled 600 patients with T1N0M0 PTC who were admitted to our hospital from June 2018 to June 2025 and confirmed by postoperative pathology. Dynamic contrast-enhanced ultrasound (CEUS) images of the thyroid and lymph nodes before surgery were collected for all patients. Two senior ultrasound physicians unaware of the pathological results independently analyzed the images and extracted qualitative and quantitative CEUS features of lesions and suspicious lymph nodes. Taking postoperative pathological results as the gold standard, patients were divided into the high-burden metastasis group, low-burden metastasis group, and non-metastasis group. Univariate and multivariate Logistic regression analyses were used to screen independent predictors, construct a combined predictive model, and draw receiver operating characteristic (ROC) curves and decision curves to evaluate its diagnostic efficacy and clinical practicality. The primary outcome measure was the area under the curve (AUC), and the secondary outcome measures included sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and net benefit. This project is expected to achieve accurate preoperative prediction of the burden of central lymph node metastasis and realize precise and individualized treatment for patients with T1N0M0 PTC.",[145,25],"Thyroid Papillary Carcinoma",[147,148],"thyroid papillary carcinoma","contrast enhanced ultrasound","2026-01-21",{"date":151,"type":34},"2026-01-22",{"date":153,"type":34},"2025-12-01",{"date":155,"type":21},"2026-12-31",{"name":157,"class":41},"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University",2,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":18,"minAge":49,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":76,"phases":169,"briefSummary":170,"conditions":171,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":42},"100617499","dceus-to-assess-treatment-response-to-prrt-in-gep-net-100617499","NCT07319416","DCEUS to Assess Treatment Response to PRRT in GEP-NET","Role of Dynamic Contrast-enhanced Ultrasound (D-CEUS) in Assessment of Response to Radioreceptor Therapy (PRRT) in Patients With Pancreatic and Gastrointestinal Tract Neuroendocrine Tumors (GEP-NET)","DCEUS-PRRT","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed diagnosis of unresectable, well-differentiated GEP-NET G2 or G3 according to WHO 2019 Classification with a Ki67 index \\> 2% up to 55%.\n* Somatostatin receptor-positive (SSTR+) disease defined by a homogenous SSTRs expression by SSA positive PET-CT or SPECT imaging.\n* At least one target lesion according to RECIST v1.1.\n* Participants must have signed and dated an approved written informed consent and must be able to comply with any study specific procedure.\n\nExclusion Criteria:\n\n* Known hypersensitivity to Lutetium 177Lu - radionuclides.\n* Other known malignancies.\n* Patients not able to declare meaningful informed consent on their own or any other vulnerable population to that.",{"count":168,"type":21},30,[78],"Neuroendocrine tumors (NETs) are a wide group of neoplasms arising from the diffuse neuroendocrine cell system that features significant molecular and biological heterogeneity. They mainly derive from the enterochromaffin cells of the gastroenteropancreatic tract (GEP-NETs) and their incidence and prevalence are steadily rising, possibly as a consequence of improving diagnostic methods and earlier detection. A major feature of GEP-NETs is their somatostatin receptor (SSTR) immunogenicity, which is relevant both for diagnostic and therapeutic purposes.\n\nFor patients with unresectable or advanced disease, systemic treatment is the standard of care. In this setting, Somatostatin analogues (SSAs) are the standard first line therapy and, even if response rates are low, disease progression is halted in about two thirds of patient. Recently, targeted radionuclide therapy has claimed significant attention as a valuable treatment option for many solid neoplasms. This approach relies on the administration of a radionuclide linked to a carrier-molecule that selectively interacts with tumor associated antigens, being eventually internalized and releasing β-radiation emission and low-energy γ rays directly from the inside of the cancer cells. Peptide Receptor Radionuclide Therapy (PRRT) is strongly recommended in progressive metastatic\u002Finoperable pretreated NETs that showed homogenous SSTRs expression by SSA positive PET-CT or single photon emission computed tomography (SPECT) imaging. Although PRRT is effective in the majority of cases, approximately 15-30% of patients will eventually progress during treatment. It is still challenging to distinguish potential responders versus non-responder patients. The identification of predictive biomarkers, apart from the required expression of somatostatin receptors, and of non-invasive diagnostic predictive exams, are an unmet need. Despite the promising clinical results, very little is known about the biological changes induced by PRRT on cancer tissue and tumor microenvironment and vascularization. The assessment of treatment' response therefore still relies on CT and PET-CT as markers of tumoral activity.\n\nAmong imaging modalities, ultrasound could play a key role in this setting. Indeed, contrast-enhanced ultrasound (CEUS) allows a thorough assessment of tumor perfusion through analysis of both contrast media flow pattern and time-intensity curves. This quantitative analysis, called dynamic contrast enhanced ultrasound (DCE-US) is a novel technique that estimates tissue perfusion based on phase-specific enhancement after the injection of microbubble contrast agents. The parameters derived from this analysis could be used for treatment monitoring in oncology, as they are easily comparable through time in each patient. In order to establish the bases for standardization of DCE-US, the European Federation of Societies for Ultrasound in Medicine and Biology (EFSUMB) recently published an update on this topic.",[172,173,25],"NET","Radionucleide Therapy","2025-12-21",{"date":176,"type":34},"2026-01-06",{"date":178,"type":34},"2025-12-11",{"date":180,"type":21},"2027-10-01",{"name":101,"class":41},{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":188,"eligibilityCriteria":189,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":190,"targetDuration":192,"studyType":22,"phases":4,"briefSummary":193,"conditions":194,"keywords":199,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":207,"locationsCount":42},"100596869","bladder-cancer-staging-and-prediction-of-new-adjuvant-chemotherapy-efficacy-based-on-deep-learning-and-transfer-learning-in-ultrasound-magnetic-resonance-pathology-multimodal-multiscale-100596869","NCT07051083","Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale","Intelligent Diagnosis of Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale","MICS-BC","Inclusion Criteria:\n\n1. Ultrasound and other imaging examinations (CT, MR, etc.) suggest bladder masses and are suspicious for bladder cancer patients.\n2. The bladder is well filled, and no allergic reactions to ultrasound contrast agents are found.\n3. No surgery or radiotherapy\u002Fchemotherapy has been performed.\n4. Patients who meet the indications for surgical resection and are planned for surgical treatment, including one of the following:\n\n   1. Clinical symptoms consistent with suspected bladder cancer (such as gross hematuria, etc.);\n   2. Patients with confirmed primary or recurrent bladder cancer by cystoscopic biopsy;\n   3. Rapid urine cytology and urine cytology FISH testing suggest malignancy.\n\nExclusion Criteria:\n\n1. Individuals unable to tolerate surgery;\n2. Individuals allergic to ultrasound contrast agents, unable to undergo ultrasound contrast examination;\n3. Unsuccessful preoperative ultrasound contrast examination or non-compliant patients;\n4. Postoperative pathology does not indicate bladder cancer;\n5. Patients who have undergone chemotherapy or radiation therapy.",{"count":191,"type":21},480,"5 Years","Bladder cancer is the most common malignant tumor of the urinary system. The presence or absence of muscle invasion in early bladder cancer is an independent prognostic factor. The involvement of muscle invasion affects the choice of surgical methods and treatment. Preoperatively, the precise assessment of bladder cancer staging has important practical value. A more accurate preoperative assessment of bladder cancer staging can reduce overtreatment and provide a favorable basis for clinicians to choose more reasonable and effective surgical methods. Clinically, there has been a longstanding desire to diagnose the staging of bladder cancer through a simple, convenient, effective, and non-invasive examination. As relevant research progresses, a multi-omics diagnostic model will be beneficial in improving diagnostic efficiency. This project aims to establish a multi-omics artificial intelligence system based on deep learning and transfer learning to accurately diagnose the staging of bladder cancer and predict the efficacy of neoadjuvant chemotherapy. This system will assist in clinical treatment decision-making.",[195,196,197,198,25],"Bladder Cancer","Staging","Deep Learning","Neoadjuvant Chemotherapy",[195,200,196,197,198,25],"Multi-omics","2025-06-26",{"date":203,"type":34},"2025-07-03",{"date":205,"type":34},"2024-01-01",{"date":155,"type":21},{"name":157,"class":41},{"id":209,"slug":210,"hasResults":11,"nctId":211,"briefTitle":212,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":18,"minAge":49,"maxAge":214,"enrollmentInfo":215,"targetDuration":216,"studyType":22,"phases":4,"briefSummary":217,"conditions":218,"keywords":222,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":228,"leadSponsor":229,"locationsCount":42},"100597110","efficacy-and-prognosis-of-microwave-ablation-treatment-for-papillary-thyroid-microcarcinoma-assessed-by-contrast-enhanced-ultrasound-combined-with-genetic-and-molecular-diagnostics-a-prospective-observational-study-100597110","NCT07054229","Efficacy and Prognosis of Microwave Ablation Treatment for Papillary Thyroid Microcarcinoma Assessed by Contrast-Enhanced Ultrasound Combined With Genetic and Molecular Diagnostics: A Prospective Observational Study","Inclusion Criteria:\n\n* Aged 18-70 years, gender not specified;\n* Patients with low-risk PTMC receiving initial treatment (meeting all the following conditions: single lesion with a maximum diameter ≤1cm; no cervical lymph node metastasis; no distant metastasis; no extrathyroidal extension; no family history of thyroid cancer; no history of head and neck radiation during childhood);\n* Patients who have undergone fine-needle aspiration cytology examination of thyroid nodules and 88-gene panel testing for thyroid cancer before surgery;\n* Patients voluntarily choose to undergo microwave ablation therapy or surgical resection.\n\nExclusion Criteria:\n\n* Tumor located in the isthmus of the thyroid;\n* Pathological high-risk subtypes (tall cell subtype, columnar cell subtype, diffuse sclerosing subtype, solid\u002Finsular subtype, oncocytic subtype);\n* Progressive enlargement of the cancer lesion in the short term (increase of more than 3mm within 6 months);\n* Pregnant women, lactating women;\n* Patients with severe coagulation disorders;\n* Patients with contralateral vocal cord dysfunction;\n* Patients with contraindications to ultrasound contrast agents;\n* Other conditions deemed ineligible for enrollment by the investigator.","70 Years",{"count":191,"type":21},"6 Months","In 2016, there were 203,000 new cases of thyroid cancer in China, ranking 7th among all malignant tumours and 4th among women, and showing a rapid growth trend. Papillary thyroid cancer (PTMC) with a diameter of ≤10 mm is the most common type of thyroid cancer, accounting for about 50% to 60% of the total number of cases. Low-risk PTMC is the most common type of thyroid cancer, with low invasiveness and good prognosis. Surgery is the treatment of choice for low-risk PTMC, but it significantly affects the quality of life of patients by affecting the function of the thyroid gland and requiring long-term medication after surgery, as well as having a high incidence of intra- and postoperative complications; there are certain impacts and limitations in the actual treatment. Microwave ablation (MWA) is a therapeutic modality emerging in recent years, which has the characteristics of easy operation, precise positioning, safety and effectiveness, small postoperative damage, fast recovery, fewer complications, and does not affect the aesthetics of the patient, which not only avoids surgical trauma and reduces the anxiety of the patient, but also better preserves the function of the thyroid gland, and its clinical application is becoming more and more widespread. In recent years, the application of microwave ablation in the treatment of PTMC has received more and more attention. Ultrasound, as a first-line examination tool, is accepted by the majority of patients because of its advantages of safety, speed, efficiency, low price and painlessness. Contrast-enhanced ultrasound (CEUS) is a new examination technique developed in recent years, which can provide richer and clearer diagnostic information than conventional ultrasound and colour Doppler ultrasound. Ultrasound contrast agents (e.g. Sonovue, Sonazoid), Sonovue with sulphur hexafluoride microbubbles as the main ingredient and Sonazoid with perfluorobutane microbubbles as the main ingredient, are non-toxic, non-radioactive, do not require allergy testing, and do not have the advantages of liver or kidney toxicity, etc., and are increasingly recognised by the public. Ultrasonography is now widely used in clinical practice as the primary modality for assessing efficacy after thyroid ablation therapy. Molecular diagnosis is one of the most important tools for preoperative diagnosis and invasiveness assessment of thyroid cancer. Common thyroid cancer gene variants include point mutations such as BRAF V600E, RAS, TP53, PIK3CA, and gene integration variants such as CCDC6-RET and ETV6-NTRK3. This project intends to assess the efficacy and prognosis of microwave ablation therapy for micropapillary thyroid cancer by ultrasonography combined with genetic molecular diagnosis, which in turn will assist in clinical treatment decisions.",[219,55,220,221],"Microwave Ablation","Genetic and Molecular Diagnostics","Papillary Thyroid Microcarcinoma",[223,221,224,220],"microwave ablation","contrast-enhanced ultrasound",{"date":226,"type":34},"2025-07-08",{"date":205,"type":34},{"date":155,"type":21},{"name":157,"class":41},{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":18,"minAge":49,"maxAge":238,"enrollmentInfo":239,"targetDuration":216,"studyType":22,"phases":4,"briefSummary":240,"conditions":241,"keywords":242,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":248,"leadSponsor":250,"locationsCount":42},"100575722","ultrasound-contrast-enhanced-accurate-diagnosis-of-preoperative-staging-of-bladder-cancer-100575722","NCT06775977","Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer","Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer: a Prospective, Observational Study","UCEADP-BCS","Inclusion Criteria:\n\n* (a) eligible patients should be 18-year-old or older;\n* (b) patients should have a histologically or cytologically confirmed diagnosis of primary bladder cancer;\n* (c) patients should not have had any surgery, chemotherapy, immunotherapy, or any therapy before CEUS diagnosis.\n\nExclusion Criteria:\n\n* (a) participants with confirmed to have no carcinoma of the bladder;\n* (b) participants with previous pelvic surgery, who had undergone therapy, any bladder surgery, or had received chemotherapy, radiotherapy or immunotherapy;\n* (c) participants diagnosed with tumor recurrence or metastasis; (d) participants who were allergic to ultrasound contrast agents or could not tolerate CEUS examination, for instance, with recent myocardial infarction, angina pectoris, cardiac insufficiency, severe cardiac arrhythmia, a right\u002Fleft cardiac shunt, severe pulmonary hypertension, uncontrolled systemic hypertension, acute respiratory distress syndrome, or chronic obstructive pulmonary disease.","75 Years",{"count":191,"type":21},"Ultrasound and magnetic resonance imaging (MRI) technologies have become essential tools for the diagnosis and preoperative staging assessment of bladder cancer. However, establishing a precise system suitable for clinical application remains a significant challenge, and accurate prediction of bladder cancer staging is not yet possible. Therefore, exploring a system for the precise diagnosis of preoperative staging of bladder cancer using ultrasound contrast enhancement or a combination of ultrasound contrast enhancement and MRI is of great importance. The applicant has previously demonstrated the accuracy of multimodal data analysis in the diagnosis and prediction of malignant tumors. Preliminary results from this study have shown that ultrasound contrast enhancement has a high diagnostic efficacy for the preoperative staging assessment of bladder cancer, with a high area under the curve (AUC) of 0.88, sensitivity of 83.3%, specificity of 92.5%, and accuracy of 90.8%. In this project, the applicant intends to further expand the sample size and, based on the combination of ultrasound contrast enhancement and MRI, develop a precise diagnostic system for the preoperative staging of bladder cancer to aid clinical treatment decisions.",[195,196,25],[195,243],"Contrast-Enhanced Ultrasonography","2025-01-21",{"date":246,"type":34},"2025-01-24",{"date":205,"type":34},{"date":249,"type":21},"2025-12-31",{"name":157,"class":41}]